Incyte’s frontMIND Hits in DLBCL – At a Toxicity Cost
Incyte’s Phase 3 frontMIND trial cut DLBCL progression risk 25% with tafasitamab + Revlimid + R-CHOP, but severe adverse events and deaths from toxicity ran ahead of standard care.
DLBCL